Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09SQM
|
|||
| Former ID |
DNCL003470
|
|||
| Drug Name |
VAY736
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Pemphigus vulgaris [ICD-11: EB40; ICD-10: L10.0, L10.1; ICD-9: 694.4] | Phase 2 | [1], [2] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [2] | ||
| Sjogren syndrome [ICD-11: 4A43.20; ICD-10: M35, M35.0] | Phase 2 | [3] | ||
| Company |
MorphoSys; Novartis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell-activating factor receptor (TNFRSF13C) | Target Info | . | [4] |
| Reactome | TNFR2 non-canonical NF-kB pathway | |||
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02137889) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients. U.S. National Institutes of Health. | |||
| REF 4 | National Cancer Institute Drug Dictionary (drug id 762784). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.